UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2022-09, Vol.23 (9), p.1133-1144

2022

Volltextzugriff (PDF)

Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma

Case reports in oncological medicine, 2021, Vol.2021, p.8870334-5

2021

Volltextzugriff (PDF)

Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity?

Journal of thoracic oncology, 2009-11, Vol.4 (11), p.1322-1330

2009

Volltextzugriff (PDF)

How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience

PloS one, 2012-12, Vol.7 (12), p.e52313-e52313

2012

Volltextzugriff (PDF)

Socioeconomic Disparities in Lung Cancer Treatment and Outcomes Persist Within a Single Academic Medical Center

Clinical lung cancer, 2012-11, Vol.13 (6), p.448-457

2012

Volltextzugriff (PDF)

Case of vemurafenib-induced Sweet's syndrome

Journal of dermatology, 2014-09, Vol.41 (9), p.817-820

2014

Volltextzugriff (PDF)

Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non–Small-Cell Lung Cancer

Clinical lung cancer, 2013-11, Vol.14 (6), p.644-650

2013

Volltextzugriff (PDF)

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature

Journal of Cancer, 2013-01, Vol.4 (4), p.320-322

2013

Volltextzugriff (PDF)

Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS6094-TPS6094

2018

Volltextzugriff (PDF)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Journal for immunotherapy of cancer, 2020-07, Vol.8 (2), p.e001009

2020

Volltextzugriff (PDF)

Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report

Journal of medical case reports, 2014-12, Vol.8 (1), p.455-455, Article 455

2014

Volltextzugriff (PDF)

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

The New England journal of medicine, 2021-08, Vol.385 (8), p.683-694

2021

Volltextzugriff (PDF)

Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.629-629

2023

Volltextzugriff (PDF)

A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas

International Journal of Surgical Oncology, 2012-01, Vol.2012 (2012), p.468-474

2012

Volltextzugriff (PDF)

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

The lancet oncology, 2024-05, Vol.25 (5), p.572-587

2024

Volltextzugriff (PDF)

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.315-315

2021

Volltextzugriff (PDF)

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2024-08, Vol.391 (8), p.710

2024

Volltextzugriff (PDF)

Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.TPS498-TPS498

2019

Volltextzugriff (PDF)

Abstract C026: Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.C026-C026

2023

Volltextzugriff (PDF)

Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT163-CT163

2018

Volltextzugriff (PDF)

Improving the care of acute lymphocytic leukemia (ALL) at a large county hospital

Journal of clinical oncology, 2013-11, Vol.31 (31_suppl), p.213-213

2013

Volltextzugriff (PDF)

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

European urology oncology, 2024-08, Vol.7 (4), p.933-943

2024

Volltextzugriff (PDF)

Assessment of absolute lymphocyte count (ALC) as a predictor of progression-free survival (PFS) and overall response rate (ORR) in metastatic melanoma (MM) patients (pts) treated with high-dose interleukin-2 (HD IL-2)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.9096-9096

2013

Volltextzugriff (PDF)

An interprofessionally developed geriatric oncology curriculum for hematology–oncology fellows

Journal of geriatric oncology, 2015-03, Vol.6 (2), p.165-173

2015

Volltextzugriff (PDF)

Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barrñ syndrome: a case report

Journal of medical case reports, 2014-12, Vol.8

2014

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(36)
Berichte
(1)

Sprache

Englisch
(37)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma

Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity?

How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience

Socioeconomic Disparities in Lung Cancer Treatment and Outcomes Persist Within a Single Academic Medical Center

Case of vemurafenib-induced Sweet's syndrome

Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non–Small-Cell Lung Cancer

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature

Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI

A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT)

Abstract C026: Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer

Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma

Improving the care of acute lymphocytic leukemia (ALL) at a large county hospital

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Assessment of absolute lymphocyte count (ALC) as a predictor of progression-free survival (PFS) and overall response rate (ORR) in metastatic melanoma (MM) patients (pts) treated with high-dose interleukin-2 (HD IL-2)

An interprofessionally developed geriatric oncology curriculum for hematology–oncology fellows

Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barrñ syndrome: a case report

Suchergebnisse filtern